Bristol Myers Squibb and Eisai forged a strategic collaboration that could be worth nearly $2.5 billion to jointly develop MORAb-202, an antibody drug conjugate (ADC) to be used against certain solid tumors across several different cancer types.
Data from clinical trials of three experimental Alzheimer’s disease drugs expected to start emerging during 2022 could help shed light on whether U.S. regulators were justified in their controversial approval of a Biogen Inc. treatment without clear evidence that Aduhelm works.
Biogen’s quest to develop additional medicines for Alzheimer’s disease beyond the company’s newly approved aducanumab hit a clinical snag as the anti-tau antibody gosuranemab failed to meet endpoints in a Phase II study and was discontinued.
German biotech CureVac NV said the company’s Covid-19 vaccine was only 47 percent effective in a late-stage trial, missing the study’s main goal and throwing in doubt the potential delivery of hundreds of millions of doses to the European Union.
Pfizer Inc.’s oral rheumatoid arthritis drug Xeljanz reduced death or respiratory failure in hospitalized Covid-19 patients with pneumonia in Brazil, meeting the study’s main goal.
Eli Lilly and Company announced the launch of a head-to-head study to compare once-monthly injectable Emgality (galcanezumab-gnlm) with Nurtec ODT (rimegepant) for the prevention of migraine.
Pivoting from conflicting and controversial press over the company’s approved Alzheimer’s disease treatment, Biogen announced that its gene therapy drug timrepigene emparvovec failed to show a clinically meaningful benefit for a rare inherited eye disease in a Phase III trial.
AstraZeneca said a late-stage trial failed to provide evidence that the company’s Covid-19 antibody therapy protected people who had contact with an infected person from the disease, a small setback in its efforts to find alternatives to vaccines.
Sage Therapeutics’ experimental depression drug showed significant improvement in symptoms compared to placebo in a late-stage study.
Novavax Inc. said vaccine efficacy appeared to be preserved in those receiving an approved influenza vaccine along with the company’s Covid-19 vaccine candidate compared to those receiving its Covid-19 vaccine alone.